Metformina Odipe (Metformin Hydrochloride)

Metformin acts mainly by inhibiting mitochondrial complex I, which reduces hepatic gluconeogenesis and consequently lowers the amount of glucose released into the bloodstream. It also enhances insulin‑mediated glucose uptake in skeletal muscle and adipose tissue, and modestly decreases intestinal glucose absorption. Activation of AMP‑activated protein kinase (AMPK) contributes to these effects and supports improved lipid metabolism.

The specific dose of Metformina Odipe is determined by the prescribing healthcare professional based on the patient’s renal function, glycemic targets, and tolerance. Typically, treatment starts with a low dose that is gradually increased to the effective maintenance dose. Patients should follow the prescriber’s instructions and not adjust the amount without medical advice.

Metformin crosses the placenta, and its safety in pregnancy is classified as category B in some regions, indicating that animal studies have not shown risk but adequate human data are lacking. It may be continued during pregnancy when the benefits outweigh potential risks, particularly in women with pre‑existing diabetes. Metformin is excreted in breast milk in small amounts; breastfeeding mothers should discuss continuation with their physician.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details—including any temperature‑controlled handling if needed—and assists with import documentation.

Compared with sulfonylureas, metformin does not stimulate insulin secretion, so it carries a lower risk of hypoglycemia. Unlike insulin, it is taken orally and does not require injection. In contrast to newer agents such as SGLT2 inhibitors, metformin is generally less expensive and has a long safety record, though it may cause gastrointestinal upset more frequently. Choice of therapy depends on individual patient characteristics and comorbidities.

Metformina Odipe tablets should be stored at room temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged. No refrigeration is required, and the tablets remain stable for the shelf life indicated on the label when stored under these conditions.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed. Dosing frequency (once or twice daily) is set by the prescriber based on the individual’s therapeutic response and tolerability. Consistent timing each day helps maintain stable blood‑glucose control.

The most critical adverse event is lactic acidosis, a rare but potentially fatal condition characterized by elevated blood lactate levels, especially in patients with renal impairment, hepatic disease, or severe infection. Severe skin reactions such as Stevens‑Johnson syndrome, and significant vitamin B12 deficiency leading to anemia or neuropathy with long‑term use, are also serious concerns. Prompt medical attention is required if symptoms such as unexplained fatigue, muscle pain, or skin blistering occur.

Metformina Odipe is contraindicated in individuals with known hypersensitivity to metformin or any component of the formulation, in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and those receiving iodinated contrast studies without appropriate discontinuation. It should also be avoided in patients with severe liver disease or conditions predisposing to hypoxia. Clinicians must assess each patient’s medical history before initiating therapy.